financetom
Business
financetom
/
Business
/
ISS recommends Vista Outdoor shareholders vote against proposed deal with CSG
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ISS recommends Vista Outdoor shareholders vote against proposed deal with CSG
Jul 11, 2024 4:28 AM

July 11 (Reuters) - Institutional Shareholder Services

has recommended Vista Outdoor ( VSTO ) shareholders to vote

against the proposed merger of the company's ammunitions unit

with Prague-based defense firm Czechoslovak Group (CSG), in a

letter seen by Reuters.

ISS wrote that MNC Capital's final buyout offer of $42 per

share "appears to be a better alternative" citing market

skepticism around Vista's forecast of doubling core profit in

fiscal 2025 from its standalone Revelyst business after the

proposed CSG deal.

On Thursday, Vista said ISS had refused to engage with the

company on the CSG transaction, and added its report did not

provide a "full and fair recommendation" to the stockholders.

Earlier this week, Vista had rejected MNC Capital's buyout

offer of $3.2 billion, and agreed to CSG's increased bid for its

ammunition unit, called the Kinetic Group.

The company had said it expects the deal to close this month

and has urged shareholders to vote for the merger with CSG at

the special meeting scheduled to be held virtually on July 23.

Vista has maintained that MNC's offer undervalues its

performance gear business, named Revelyst, and added in a letter

to stockholders on Wednesday it may consider pursuing strategic

alternatives for the unit at the "appropriate" time and

valuation.

The Federal Ammunition and Remington Ammunition owner also

said a vote against the CSG deal at the special meeting would

not mean the company's board would negotiate with MNC Capital.

MNC Capital did not immediately respond to a Reuters request

for comment.

ISS had previously recommended Vista shareholders to abstain

from voting on a proposed merger during the special meeting.

On closing of the CSG deal, which has received regulatory

approval from an interagency committee of the U.S. government,

Vista's stockholders will receive one share of Revelyst common

stock and $21 in cash apiece.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Yum! Brands' Q3 Non-GAAP Earnings, Revenue Increase
Yum! Brands' Q3 Non-GAAP Earnings, Revenue Increase
Nov 4, 2025
07:25 AM EST, 11/04/2025 (MT Newswires) -- Yum! Brands ( YUM ) reported Q3 non-GAAP earnings Tuesday of $1.58 per share, up from $1.37 a year earlier. Analysts polled by FactSet expected $1.49. Revenue for the quarter ended Sept. 30 was $1.98 billion, compared with $1.83 billion a year earlier. Analysts polled by FactSet expected $2 billion. The company said...
First Watch Restaurant Group beats Q3 revenue estimates
First Watch Restaurant Group beats Q3 revenue estimates
Nov 4, 2025
Overview * First Watch Q3 revenue grows 25.6% yr/yr, beating analyst expectations * Adjusted EBITDA for Q3 beats consensus, reflecting strong operational performance * Company opened 21 new restaurants in 14 states, expanding its footprint Outlook * First Watch expects FY25 adjusted EBITDA of ~$123 mln * Company forecasts FY25 same-restaurant sales growth of ~4%, total rev growth of 20-21%...
Pfizer raises 2025 profit forecast for second quarter in a row
Pfizer raises 2025 profit forecast for second quarter in a row
Nov 4, 2025
Nov 4 (Reuters) - Pfizer ( PFE ) on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster blood thinner helped it post third-quarter earnings above expectations. The drugmaker, which stuck to its full-year revenue forecast for the year, has benefited from CEO Albert Bourla's cost-cutting initiatives, new product launches...
Madrigal Pharma Q3 revenue rises on Rezdiffra demand
Madrigal Pharma Q3 revenue rises on Rezdiffra demand
Nov 4, 2025
Overview * Madrigal Q3 revenue rises to $287.3 mln, driven by Rezdiffra demand * Company reports a net loss for Q3 despite revenue growth * Madrigal closes global licensing deal with CSPC Pharma for oral GLP-1 Outlook * Madrigal expects Rezdiffra sales to grow in 2026 * Company plans to start clinical trials for oral GLP-1 in H1 2026 *...
Copyright 2023-2026 - www.financetom.com All Rights Reserved